Published in Cell on May 14, 2009
mTOR signaling in growth control and disease. Cell (2012) 29.21
mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol (2010) 21.16
mTOR signaling at a glance. J Cell Sci (2009) 8.66
Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell (2010) 7.59
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy (2016) 7.05
mTOR regulation of autophagy. FEBS Lett (2010) 6.59
mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell (2011) 4.70
With TOR, less is more: a key role for the conserved nutrient-sensing TOR pathway in aging. Cell Metab (2010) 4.11
Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol Cell Biol (2009) 3.32
mTOR and cancer: many loops in one pathway. Curr Opin Cell Biol (2009) 3.22
Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest (2011) 3.00
Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J Biol Chem (2010) 2.90
Regulation and function of mTOR signalling in T cell fate decisions. Nat Rev Immunol (2012) 2.79
mTOR complex 2 signaling and functions. Cell Cycle (2011) 2.66
Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes (2010) 2.65
Regulation of mTORC1 by amino acids. Trends Cell Biol (2014) 2.64
mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Mol Cell Biol (2009) 2.57
Mechanisms and function of substrate recruitment by F-box proteins. Nat Rev Mol Cell Biol (2013) 2.56
The mTOR signalling pathway in human cancer. Int J Mol Sci (2012) 2.38
Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene (2010) 2.22
TOR-dependent control of autophagy: biting the hand that feeds. Curr Opin Cell Biol (2009) 2.17
mTOR drives its own activation via SCF(βTrCP)-dependent degradation of the mTOR inhibitor DEPTOR. Mol Cell (2011) 2.03
A comprehensive glossary of autophagy-related molecules and processes (2nd edition). Autophagy (2011) 2.02
A comprehensive glossary of autophagy-related molecules and processes. Autophagy (2010) 2.00
A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. Cancer Discov (2014) 1.99
Physiological regulation of Akt activity and stability. Am J Transl Res (2010) 1.95
mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action. J Biol Chem (2009) 1.93
Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica (2009) 1.87
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget (2012) 1.85
Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation. Blood (2013) 1.85
DEPTOR, an mTOR inhibitor, is a physiological substrate of SCF(βTrCP) E3 ubiquitin ligase and regulates survival and autophagy. Mol Cell (2011) 1.85
mTOR generates an auto-amplification loop by triggering the βTrCP- and CK1α-dependent degradation of DEPTOR. Mol Cell (2011) 1.78
The targets of curcumin. Curr Drug Targets (2011) 1.76
MicroRNA-21 orchestrates high glucose-induced signals to TOR complex 1, resulting in renal cell pathology in diabetes. J Biol Chem (2011) 1.70
mTOR signaling in glioblastoma: lessons learned from bench to bedside. Neuro Oncol (2010) 1.65
Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein. J Clin Oncol (2011) 1.65
mTOR: a pharmacologic target for autophagy regulation. J Clin Invest (2015) 1.61
A comprehensive map of the mTOR signaling network. Mol Syst Biol (2010) 1.59
Inactivation of Rheb by PRAK-mediated phosphorylation is essential for energy-depletion-induced suppression of mTORC1. Nat Cell Biol (2011) 1.59
mTOR: on target for novel therapeutic strategies in the nervous system. Trends Mol Med (2012) 1.59
Mammalian target of rapamycin signaling in cardiac physiology and disease. Circ Res (2014) 1.59
A Central role for mTOR in lipid homeostasis. Cell Metab (2013) 1.57
TRIMs and Galectins Globally Cooperate and TRIM16 and Galectin-3 Co-direct Autophagy in Endomembrane Damage Homeostasis. Dev Cell (2016) 1.56
GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget (2014) 1.56
Regulation of mTORC1 by PI3K signaling. Trends Cell Biol (2015) 1.54
Regulation of mTOR complex 1 (mTORC1) by raptor Ser863 and multisite phosphorylation. J Biol Chem (2009) 1.53
The human papillomavirus type 16 E6 oncoprotein activates mTORC1 signaling and increases protein synthesis. J Virol (2010) 1.49
Organ size control by Hippo and TOR pathways. Curr Biol (2012) 1.45
Autophagy as a target for cancer therapy: new developments. Cancer Manag Res (2012) 1.44
Rapamycin inhibits cytoskeleton reorganization and cell motility by suppressing RhoA expression and activity. J Biol Chem (2010) 1.44
Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production. Blood (2010) 1.44
The role of autophagy in tumour development and cancer therapy. Expert Rev Mol Med (2009) 1.43
Emerging role of autophagy in kidney function, diseases and aging. Autophagy (2012) 1.43
mTOR complexes in neurodevelopmental and neuropsychiatric disorders. Nat Neurosci (2013) 1.43
Autophagy: controlling cell fate in rheumatic diseases. Nat Rev Rheumatol (2016) 1.42
Nutrient regulation of the mTOR complex 1 signaling pathway. Mol Cells (2013) 1.42
Protein kinase signaling networks in cancer. Curr Opin Genet Dev (2010) 1.41
mTOR Mediated Anti-Cancer Drug Discovery. Drug Discov Today Ther Strateg (2009) 1.41
mTORC2 critically regulates renal potassium handling. J Clin Invest (2016) 1.40
mTOR signaling for biological control and cancer. J Cell Physiol (2013) 1.40
Rapamycin-resistant mTORC1 kinase activity is required for herpesvirus replication. J Virol (2010) 1.38
Pushing the envelope in the mTOR pathway: the second generation of inhibitors. Mol Cancer Ther (2011) 1.38
What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway. Cancer Discov (2013) 1.38
Role of mTOR signaling in tumor cell motility, invasion and metastasis. Curr Protein Pept Sci (2011) 1.37
Resveratrol inhibits mTOR signaling by promoting the interaction between mTOR and DEPTOR. J Biol Chem (2010) 1.35
Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. Blood (2010) 1.35
The CK1 Family: Contribution to Cellular Stress Response and Its Role in Carcinogenesis. Front Oncol (2014) 1.33
The complexes of mammalian target of rapamycin. Curr Protein Pept Sci (2010) 1.33
Growing knowledge of the mTOR signaling network. Semin Cell Dev Biol (2014) 1.33
Significance of SGK1 in the regulation of neuronal function. J Physiol (2010) 1.32
Mammalian target of rapamycin complex 2 (mTORC2) negatively regulates Toll-like receptor 4-mediated inflammatory response via FoxO1. J Biol Chem (2011) 1.31
Amino acids activate mammalian target of rapamycin complex 2 (mTORC2) via PI3K/Akt signaling. J Biol Chem (2010) 1.30
An emerging role for TOR signaling in mammalian tissue and stem cell physiology. Development (2011) 1.27
A novel molecular signature identified by systems genetics approach predicts prognosis in oral squamous cell carcinoma. PLoS One (2011) 1.27
mTOR-dependent cell survival mechanisms. Cold Spring Harb Perspect Biol (2012) 1.24
Regulation of TOR by small GTPases. EMBO Rep (2012) 1.24
Inhibition of Notch uncouples Akt activation from hepatic lipid accumulation by decreasing mTorc1 stability. Nat Med (2013) 1.23
Phosphatidic acid activates mammalian target of rapamycin complex 1 (mTORC1) kinase by displacing FK506 binding protein 38 (FKBP38) and exerting an allosteric effect. J Biol Chem (2011) 1.22
Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders. Oxid Med Cell Longev (2010) 1.21
Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC/Rheb-independent manner. Proc Natl Acad Sci U S A (2011) 1.20
mTOR kinase domain phosphorylation promotes mTORC1 signaling, cell growth, and cell cycle progression. Mol Cell Biol (2011) 1.19
Review series: TOR kinase complexes and cell migration. J Cell Biol (2011) 1.19
Cullin-RING Ligases as attractive anti-cancer targets. Curr Pharm Des (2013) 1.19
Omega-3 polyunsaturated fatty acids augment the muscle protein anabolic response to hyperinsulinaemia-hyperaminoacidaemia in healthy young and middle-aged men and women. Clin Sci (Lond) (2011) 1.17
Phosphorylation of AKT: a mutational analysis. Oncotarget (2011) 1.17
Targeting Cullin-RING ligases by MLN4924 induces autophagy via modulating the HIF1-REDD1-TSC1-mTORC1-DEPTOR axis. Cell Death Dis (2012) 1.17
Raptor is phosphorylated by cdc2 during mitosis. PLoS One (2010) 1.17
Akt and mTOR in B Cell Activation and Differentiation. Front Immunol (2012) 1.16
Deconvoluting mTOR biology. Cell Cycle (2012) 1.16
mTor signaling in skeletal muscle during sepsis and inflammation: where does it all go wrong? Physiology (Bethesda) (2011) 1.16
Rictor phosphorylation on the Thr-1135 site does not require mammalian target of rapamycin complex 2. Mol Cancer Res (2010) 1.15
DEPTOR cell-autonomously promotes adipogenesis, and its expression is associated with obesity. Cell Metab (2012) 1.15
Differential requirement of CAAX-mediated posttranslational processing for Rheb localization and signaling. Oncogene (2009) 1.14
Enhancing mTOR-targeted cancer therapy. Expert Opin Ther Targets (2009) 1.13
Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin. Prog Neurobiol (2012) 1.13
Regulation of mRNA translation by signaling pathways. Cold Spring Harb Perspect Biol (2012) 1.13
Genome-wide analysis of glucocorticoid receptor-binding sites in myotubes identifies gene networks modulating insulin signaling. Proc Natl Acad Sci U S A (2012) 1.12
Targeting SREBP-1-driven lipid metabolism to treat cancer. Curr Pharm Des (2014) 1.11
The Mechanistic Target of Rapamycin: The Grand ConducTOR of Metabolism and Aging. Cell Metab (2016) 1.10
Defining the role of TORC1/2 in multiple myeloma. Blood (2011) 1.10
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 38.99
Defining the role of mTOR in cancer. Cancer Cell (2007) 21.63
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res (2006) 18.44
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell (2006) 18.36
Cellular survival: a play in three Akts. Genes Dev (1999) 17.05
An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem (2009) 12.73
mTOR and cancer: insights into a complex relationship. Nat Rev Cancer (2006) 11.86
Growing roles for the mTOR pathway. Curr Opin Cell Biol (2005) 11.66
Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science (1997) 11.48
PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell (2007) 9.68
Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol (2009) 9.63
Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell (1995) 9.22
Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev (1999) 8.14
RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci U S A (1998) 8.03
Effects of aneuploidy on cellular physiology and cell division in haploid yeast. Science (2007) 7.69
mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J (2008) 7.18
Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science (1997) 7.07
Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci U S A (2008) 6.84
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood (2002) 5.47
Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev (2001) 5.37
Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer (2002) 5.30
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell (2006) 5.01
Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci U S A (2003) 4.47
The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene (2008) 4.39
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood (2005) 4.04
Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Mol Cell (2008) 3.91
Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. Cancer Cell (2006) 3.83
Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell (2004) 3.55
PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest (2007) 3.54
Exploitation of KESTREL to identify NDRG family members as physiological substrates for SGK1 and GSK3. Biochem J (2004) 3.39
Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev (2005) 3.25
Profiling of UV-induced ATM/ATR signaling pathways. Proc Natl Acad Sci U S A (2007) 3.12
mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation. Mol Cell (2008) 3.06
PDZ proteins interacting with C-terminal GluR2/3 are involved in a PKC-dependent regulation of AMPA receptors at hippocampal synapses. Neuron (2000) 2.56
Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res (2007) 2.50
Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood (1998) 2.36
Discovery of PDK1, one of the missing links in insulin signal transduction. Colworth Medal Lecture. Biochem Soc Trans (2001) 2.12
Association of Dishevelled with the clathrin AP-2 adaptor is required for Frizzled endocytosis and planar cell polarity signaling. Dev Cell (2007) 1.99
DEP-domain-mediated regulation of GPCR signaling responses. Cell (2006) 1.87
An antagonist of dishevelled protein-protein interaction suppresses beta-catenin-dependent tumor cell growth. Cancer Res (2007) 1.73
A new MAFia in cancer. Nat Rev Cancer (2008) 1.70
PDZ domains: folding and binding. Biochemistry (2007) 1.68
Analysis of PTEN deletions and mutations in multiple myeloma. Leuk Res (2005) 1.56
Serum and glucocorticoid-regulated protein kinases: variations on a theme. J Cell Biochem (2006) 1.42
DEP domains: More than just membrane anchors. Dev Cell (2006) 1.14
Purification and characterization of a Z-Leu-Leu-Leu-MCA degrading protease expected to regulate neurite formation: a novel catalytic activity in proteasome. Biochem Biophys Res Commun (1993) 1.13
Plasma cell differentiation and multiple myeloma. Curr Opin Immunol (2004) 1.08
Identification of primary MAFB target genes in multiple myeloma. Exp Hematol (2008) 1.06
Frap, FKBP12 rapamycin-associated protein, is a candidate gene for the plasmacytoma resistance locus Pctr2 and can act as a tumor suppressor gene. Proc Natl Acad Sci U S A (2003) 1.02
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 38.99
CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol (2006) 32.51
mTOR signaling in growth control and disease. Cell (2012) 29.21
Defining the role of mTOR in cancer. Cancer Cell (2007) 21.63
mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol (2010) 21.16
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell (2006) 18.81
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell (2006) 18.36
mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell (2002) 18.22
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol (2004) 16.83
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
CellProfiler: free, versatile software for automated biological image analysis. Biotechniques (2007) 14.71
The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science (2008) 14.08
An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem (2009) 12.73
Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell (2010) 12.24
Evaluation of multidimensional chromatography coupled with tandem mass spectrometry (LC/LC-MS/MS) for large-scale protein analysis: the yeast proteome. J Proteome Res (2003) 11.96
Cancer cell metabolism: Warburg and beyond. Cell (2008) 11.80
Growing roles for the mTOR pathway. Curr Opin Cell Biol (2005) 11.66
Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell (2006) 11.48
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
Genetic screens in human cells using the CRISPR-Cas9 system. Science (2013) 10.75
A proteomics approach to understanding protein ubiquitination. Nat Biotechnol (2003) 10.51
PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell (2007) 9.68
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res (2008) 9.29
Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer (2009) 9.26
Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest (2007) 8.71
mTOR signaling at a glance. J Cell Sci (2009) 8.66
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A (2007) 8.23
Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA (2003) 8.07
Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature (2011) 8.03
Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell (2010) 7.59
mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H(+)-ATPase. Science (2011) 7.55
Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A (2008) 7.45
The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol Cell Biol (2002) 7.44
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell (2007) 7.10
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature (2009) 7.05
Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature (2008) 6.80
The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science (2011) 6.75
Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res (2008) 6.71
Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science (2012) 6.69
MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A (2009) 6.58
Integrative genomics identifies MCU as an essential component of the mitochondrial calcium uniporter. Nature (2011) 6.48
A unifying model for mTORC1-mediated regulation of mRNA translation. Nature (2012) 6.44
Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods (2006) 5.96
The pharmacology of mTOR inhibition. Sci Signal (2009) 5.36
GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell (2003) 5.21
Scoring diverse cellular morphologies in image-based screens with iterative feedback and machine learning. Proc Natl Acad Sci U S A (2009) 5.15
mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol (2006) 5.06
A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. EMBO J (2012) 5.03
Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol (2006) 5.03
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. Proc Natl Acad Sci U S A (2008) 4.80
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov (2011) 4.80
Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol (2002) 4.77
mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell (2011) 4.70
Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res (2004) 4.54
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res (2011) 4.22
Advances in biology of multiple myeloma: clinical applications. Blood (2004) 4.13
Genome-scale loss-of-function screening with a lentiviral RNAi library. Nat Methods (2006) 4.12
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood (2005) 4.04
TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr Biol (2003) 4.01
A monoclonal gammopathy precedes multiple myeloma in most patients. Blood (2009) 3.98
A Tumor suppressor complex with GAP activity for the Rag GTPases that signal amino acid sufficiency to mTORC1. Science (2013) 3.96
Functional genomics, proteomics, and regulatory DNA analysis in isogenic settings using zinc finger nuclease-driven transgenesis into a safe harbor locus in the human genome. Genome Res (2010) 3.94
Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol (2005) 3.93
Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci U S A (2006) 3.83
mTORC1 controls fasting-induced ketogenesis and its modulation by ageing. Nature (2010) 3.81
mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell (2009) 3.78
Ragulator is a GEF for the rag GTPases that signal amino acid levels to mTORC1. Cell (2012) 3.77
Tumours with PI3K activation are resistant to dietary restriction. Nature (2009) 3.60
Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell (2004) 3.55
mTORC1 in the Paneth cell niche couples intestinal stem-cell function to calorie intake. Nature (2012) 3.51
An emerging role of mTOR in lipid biosynthesis. Curr Biol (2009) 3.50
An expanding role for mTOR in cancer. Trends Mol Med (2005) 3.40
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature (2010) 3.39
Structure of the human mTOR complex I and its implications for rapamycin inhibition. Mol Cell (2010) 3.33
Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One (2011) 3.23
mTOR and cancer: many loops in one pathway. Curr Opin Cell Biol (2009) 3.22
Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol (2008) 3.18
The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res (2010) 3.16
Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood (2006) 3.13
A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology (2003) 3.04
Cancer cell metabolism: one hallmark, many faces. Cancer Discov (2012) 3.03
CellProfiler Analyst: data exploration and analysis software for complex image-based screens. BMC Bioinformatics (2008) 2.99
Engineered ascorbate peroxidase as a genetically encoded reporter for electron microscopy. Nat Biotechnol (2012) 2.98